Related Experiment Video

Updated: Mar 29, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.9K

Antiplatelet effects of aspirin in chronic kidney disease patients

A Polzin1, L Dannenberg1, R Sansone1

  • 1Division of Cardiology, Pulmonology and Vascular Medicine, Heinrich Heine University Medical Center Dusseldorf, Dusseldorf, Germany.

Journal of Thrombosis and Haemostasis : JTH
|December 9, 2015
PubMed

Insights

Patients with chronic kidney disease (CKD) often experience reduced antiplatelet effects from aspirin, increasing cardiovascular risk. Further research is needed to determine optimal antithrombotic strategies for this population.

Area of Science:

  • Cardiovascular Medicine
  • Nephrology
  • Pharmacology

Background:

  • Chronic kidney disease (CKD) patients face elevated cardiovascular event risks.
  • Individual responses to aspirin vary, with insufficient antiplatelet effects linked to ischemic events.
  • CKD may impact the pharmacodynamic response to antiplatelet drugs, similar to clopidogrel's known effects.

Purpose of the Study:

  • To investigate the antiplatelet effects of aspirin in patients diagnosed with CKD.
  • To evaluate the relationship between renal function and aspirin's pharmacodynamic response.

Main Methods:

  • A cross-sectional study involving 116 patients on long-term aspirin therapy.
  • Pharmacodynamic assessment of aspirin's effect using arachidonic acid-induced thromboxane formation.

Main Results:

  • High on-treatment platelet reactivity (HTPR) to aspirin was significantly more common in patients with impaired renal function (47% vs. 22%).
  • Aspirin's pharmacodynamic response was impaired in moderate/severe CKD patients compared to those with normal/mildly reduced renal function.
  • Residual thromboxane formation correlated with glomerular filtration rate, independent of age and gender.

Conclusions:

  • Renal function is a key factor influencing the pharmacodynamic response to aspirin.
  • CKD patients are at a higher risk of experiencing diminished antiplatelet effects from aspirin.
  • Larger trials are necessary to confirm clinical impact and establish optimal antithrombotic regimens for CKD patients.
Abstract

Keywords:
aspirinchronic kidney diseasedrug resistanceplatelet activationplatelet function

More Related Videos

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor06:32

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

894
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.8K

Related Concept Videos

Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
482
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
330
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
945
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
620
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
306